Development Center for Biotechnology

National Health Research Institutes

Dcb-usa LLC

Chia-Cheng Wu

Ko-Jiunn Liu

Neng-Yao Shih

Chao-Yang Huang

Ta-Tung Yuan

Jiann-Shiun Lai

Shih-Chong Tsai

Li-Tzong Chen

Ying-Yung Lok

Shih-Chi Tseng

Chung-Hsiun Wu

Ya-Wei Tsai

Yi-Jen Chen

Shih-Hsien Chuang

Chih-Yung Hu

Szu-Liang Lai

Win-Yin Wei

Chuan-Lung Hsu

Chao-Pin Lee

Yu-Chin Nieh

Hsien-Yu Tsai

Yu-Jung Chen

Po-Yin Lin

Tzu-Yin Lin

Jiann-shiun Lai

Yu-Ying Lin

An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab&#x2212;(L&#x2212;D), wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.

Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof

An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

Antibodies specific to alpha-enolase and uses thereof

A humanized anti-Globo H antibody, or an scFv or Fab fragment thereof, comprising a heavy-chain variable domain having three complementary regions consisting of HCDR1, HCDR2, and HCDR3 and a light-chain variable domain having three complementary regions consisting of LCDR1, LCDR2, and LCDR3, wherein the sequence of HCDR1 is GYISSDQILN (SEQ ID NO:4), the sequence of HCDR2 is RIYPVTGVTQYXHKFVG (SEQ ID NO:5, wherein X is any amino acid), and the sequence of HCDR3 is GETFDS (SEQ ID NO:6), wherein the sequence of LCDR1 is KSNQNLLX'SGNRRYZLV (SEQ ID NO:7, wherein X&#x2032; is F, Y, or W, and Z is C, G, S or T), the sequence of LCDR2 is WASDRSF (SEQ ID NO:8), and the sequence of LCDR3 is QQHLDIPYT (SEQ ID NO:9).

Humanized antibodies against Globo H and uses thereof in cancer treatments

A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy

Growing community of inventors

Taipei, Taiwan

Chia-Cheng Wu